A Study of IBI363 in Subjects with Advanced Solid Malignancies
A phase 2 trial of IBI363 in melanoma and non-small-cell lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
Overview
A Study of IBI363 in Subjects with Advanced Solid Malignancies is a phase 2 interventional study registered as NCT06281678 by Innovent Biologics (Suzhou) Co. Ltd., with 178 participants planned, started 2024-04-08 and due to reach its primary completion in 2026-03-01. Interventions recorded: IBI363. Conditions listed: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of IBI363 in Subjects With Advanced Melanoma
Shares IBI363, Innovent Biologics, Melanoma.
- TrialA Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat
Shares IBI363, Innovent Biologics, Melanoma.
- TrialIBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Shares IBI363, Innovent Biologics, Colorectal cancer.
- TrialIBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small
Shares IBI363, Innovent Biologics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialNeoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
Shares Innovent Biologics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialORIENT-11
- TreatmentFulzerasib